In this context, it has been suggested in epidemiological studies that the metabolism of nicotinamide, specifically the enzyme nicotinamide N-methyl-transferase (NNMT), could contribute to behavioral and neurodegenerative diseases such as Parkinson’s disease (PD) and schizophrenia. Here, NNMT is linked to schizophrenia.